(20S)-Protopanaxatriol 产品活性：(20S)-Protopanaxatriol 是人参皂苷的代谢物，通过结合糖皮质激素受体 (glucocorticoid receptor) 和雌激素受体 (Estrogen Receptor/ERR) 起作用。(20S)-Protopanaxatriol 同时也是 LXRα 的抑制剂。(20S)-Protopanaxatriol 具有广泛的抗癌活性。 产品来源： https://www.medchemexpress.cn/_20S_-Protopanaxatriol.html 研究领域：Immunology/Inflammation | Vitamin D Related/Nuclear Receptor | Metabolic Enzyme/Protease | Apoptosis 作用靶点：Glucocorticoid Receptor | Estrogen Receptor/ERR | LXR | Apoptosis 来源：植物 | 五加科 | 人参 结构分类：萜类 | 三萜 | 结构分类 In Vitro: (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and oestrogen receptor (ER) in human umbilical vein endothelial cells (HUVECs). (20S)-Protopanaxatriol (PPT) increases [Ca2+]i with an EC50 of 482 nM in HUVECs. ((20S)-Protopanaxatriol (1 µM) elevates NO production via ERβ. (20S)-Protopanaxatriol inhibits the autonomous transactivation of Gal4-LXRα LBD, the T0901317-dependent transcription of SREBP-1c and its promoter. (20S)-Protopanaxatriol (10 μg/mL) blocks the recruitment of RNA polymerase II to the LXRE region of SREBP-1c. (20S)-Protopanaxatriol also inhibits T0901317-dependent transcription of LXRα target genes related to lipogenesis, and reduces T0901317-induced cellular triglyceride (TG) accumulation in primary hepatocytes, but does not alter transcription of ABCA1, also an LXRα target gene. Both In HCC827GR and H1975 cell lines, g-PPT (100 nM, 1 μM, 10 μM, 20 μM; 48 hours) results in SCD1 expression decreased. In Vivo: (20S)-Protopanaxatriol (10 mg/kg; i.p.; daily for four weeks) synergizes with Gefitinib to inhibit xenograft growth. (20S)-Protopanaxatriol (50-100 mg/kg; p.o.; 25 days; female BALB/c nude mice bearing breast cancer MCF-7 cell) inhibits the growth of MCF-7 breast cancer cells in a nude mice xenograft assay. 相关产品：Natural Product Library Plus | Bioactive Compound Library Plus | Apoptosis Compound Library | Immunology/Inflammation Compound Library | Metabolism/Protease Compound Library | Natural Product Library | Lipid Compound Library | Anti-Cardiovascular Disease Compound Library | Endocrinology Compound Library | Medicine Food Homology Compound Library | Terpenoids Library | Traditional Chinese Medicine Active Compound Library | Anti-Breast Cancer Compound Library | Lipid Metabolism Compound Library | Anti-inflammatory Traditional Chinese Medicine Active Compound Library | Plant-Sourced Natural Product Library | Nuclear Receptor Compound Library | Pain-Related Compound Library | Metabolic Enzyme Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Cell Death Library | Multi-Target Compound Library | Bioactive Compound Library Max | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Y-27632 | LY294002 | Paclitaxel | Dexamethasone | Z-VAD-FMK | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Deferoxamine mesylate | Oxaliplatin | Trametinib | Sorafenib | Temozolomide | Gemcitabine | Decitabine | Mdivi-1 | Rotenone | Etoposide | Elesclomol | Hydrocortisone | Ruxolitinib 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。